PubRank

Atul Humar

Author PubWeight™ 92.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010 4.00
2 West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ 2003 3.03
3 Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013 2.43
4 Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 2007 2.35
5 Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 2.23
6 Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004 2.11
7 Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010 1.98
8 RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010 1.94
9 Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007 1.78
10 Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009 1.64
11 Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009 1.60
12 Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005 1.45
13 Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis 2002 1.37
14 A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010 1.35
15 Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2012 1.25
16 An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005 1.14
17 State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012 1.10
18 Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol 2010 1.09
19 A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant 2004 1.09
20 Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004 1.08
21 The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011 1.07
22 Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 2005 1.05
23 A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis 2005 1.05
24 Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009 1.05
25 Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005 1.02
26 Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012 1.00
27 A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007 1.00
28 Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003 0.98
29 Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005 0.98
30 Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J Clin Virol 2002 0.97
31 A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation 2007 0.97
32 An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010 0.97
33 Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. J Clin Microbiol 2008 0.97
34 Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004 0.95
35 Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008 0.95
36 Unrecognized pretransplant and donor‐derived cryptococcal disease in organ transplant recipients. Clin Infect Dis 2010 0.94
37 Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2007 0.94
38 Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005 0.93
39 Graphium basitruncatum fungemia in a patient with acute leukemia. J Clin Microbiol 2007 0.93
40 Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003 0.93
41 Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis 2010 0.93
42 Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis 2013 0.92
43 Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005 0.92
44 Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 2008 0.92
45 Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 2011 0.91
46 Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry? Am J Transplant 2003 0.91
47 A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008 0.90
48 A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011 0.89
49 Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation 2013 0.88
50 Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant 2011 0.87
51 The production of transgenic pigs for potential use in clinical xenotransplantation: microbiological evaluation. Xenotransplantation 2002 0.86
52 Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med 2004 0.85
53 Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006 0.85
54 The production of transgenic pigs for potential use in clinical xenotransplantation: baseline clinical pathology and organ size studies. Xenotransplantation 2002 0.84
55 An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis 2009 0.84
56 Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008 0.84
57 An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One 2012 0.83
58 Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. Pediatr Transplant 2010 0.82
59 Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis. Transplantation 2012 0.82
60 Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am 2010 0.82
61 Long term immune responses to pandemic influenza A/H1N1 infection in solid organ transplant recipients. PLoS One 2011 0.82
62 Life-threatening infection in transplant recipients. Crit Care Clin 2013 0.82
63 A novel model to study bacterial adherence to the transplanted airway: inhibition of Burkholderia cepacia adherence to human airway by dextran and xylitol. J Heart Lung Transplant 2004 0.82
64 Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. Transplantation 2016 0.81
65 Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis 2002 0.80
66 Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period. Transplantation 2014 0.79
67 Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology. J Heart Lung Transplant 2009 0.79
68 Microbial contamination of clinical islet transplant preparations is associated with very low risk of infection. Diabetes Technol Ther 2013 0.79
69 Cytomegalovirus prophylaxis: how long is enough? Nat Rev Nephrol 2010 0.79
70 Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003 0.79
71 Human cytomegalovirus infection in humanized liver chimeric mice. Hepatol Res 2013 0.79
72 Treatment of cytomegalovirus disease in solid organ transplant recipients: markers of inflammation as predictors of outcome. Transplantation 2012 0.78
73 Tuberculosis and transplantation: battling the opportunist. Clin Infect Dis 2009 0.78
74 Severe acute respiratory syndrome and the liver. Hepatology 2004 0.78
75 Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation 2010 0.78
76 Modulation of the inhibitory receptor leukocyte Ig-like receptor 1 on human natural killer cells. Front Immunol 2011 0.78
77 Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. J Clin Virol 2012 0.78
78 Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. Transplantation 2010 0.78
79 Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma. PLoS One 2013 0.78
80 Emerging viral infections in transplant recipients. Curr Opin Infect Dis 2005 0.77
81 Response to questions regarding the design and results of the IMPACT trial. Am J Transplant 2011 0.77
82 Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1). J Heart Lung Transplant 2010 0.76
83 Increased osteoprotegerin predicts poor virological outcome during anticytomegalovirus therapy in solid organ transplant recipients. Transplantation 2015 0.76
84 Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009 0.76
85 Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients. Transplantation 2017 0.76
86 Public Solicitation of Anonymous Organ Donors: A Position Paper by the Canadian Society of Transplantation. Transplantation 2017 0.75
87 Screening for West Nile virus: more uncertainty. Am J Transplant 2004 0.75
88 Understanding risk and enhancing safety in immunotherapy trials. Clin Infect Dis 2012 0.75
89 Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: a randomized clinical trial. Transplantation 2015 0.75
90 Outbreak of pseudomonas aeruginosa by multiple organ transplantation from a common donor. Transplantation 2003 0.75
91 Control of microbial contamination during surgical harvest of pig renal xenografts. Xenotransplantation 2004 0.75
92 Cytomegalovirus in the Pediatric Transplant Recipient: where are we now? Transplantation 2016 0.75
93 Probable interaction between efavirenz and cyclosporine. AIDS 2002 0.75
94 Humoral immune response following seasonal influenza vaccine in islet transplant recipients. Cell Transplant 2012 0.75
95 QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy. Clin Rheumatol 2013 0.75
96 A Survey of Increased Infectious Risk Donor Utilization in Canadian Transplant Programs. Transplantation 2016 0.75
97 Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. Transplantation 2010 0.75